Mobility devices co makes maiden Dx buy with 180º turntowards pharma and biotech strategy
This article was originally published in Clinica
Executive Summary
Heralding a complete U-turn in its strategic direction, mobility products company Modern Mobility Aids (MMA) has agreed to purchase Canadian molecular diagnostics specialist LumiGene Technologies. MMA will pay Can$1m ($1.02m) upfront for LumiGene, as well as 2% of all gross revenue realised from the business after the deal has closed and up to Can$480,000 in additional milestone payments.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.